In addition, a mouse model study showed that, at the two-time points of onset of NASH progression and HCC survival, combined treatment with pemafibrate and tofogliflozin (an SGLT-2 inhibitor) not only significantly relieved hyperglycemia and hypertriglyceridemia but also reduced ballooning of hepatocytes, reduced expression of ER stress-related genes level (such as Ire1a, Grp78, Xbp1, and Phlda3), and significantly improved the survival rate and decreased the tumors' numbers in the liver. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.